CD274 and non-small cell lung carcinoma: A phase 2, single‐arm, multicenter trial involving NSCLC patients demonstrated the safety of the first FDA‐approved ICI targeting PD‐1/PD‐L1 (nivolumab), in which grade 3–4 manageable adverse events were observed in 17% of 117 patients [26].